Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition: HER2-positive Early Breast Cancer
NCT07340398
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | few_sites_large_trial_signal | rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.